πŸ“£ VC round data is live. Check it out!

Largest Nutraceuticals & Cosmeceuticals Public Companies in South Korea

Benchmark revenue and EBITDA valuation multiples for public comps like Hugel, Medy-Tox, Chong Kun Dang Holdings and Hyundai Bioland Co.

Reset all filters
South Korea
Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing of biopharmaceuticals. The company's primary products are Botulinum toxin, Hyaluronic acid filler, and Cosmetics. It develops and promotes its products under the brand name of Wellage. The firm has manufacturing facilities in Shinbuk and Geodu.
$200
-11%
$2B
$2B
6.2x
11.9x
South Korea
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.
$71
-38%
$466M
$485M
2.9x
26.0x
South Korea
Chong Kun Dang Holdings Corp manufactures and markets medicines and active pharmaceutical ingredients. It offers prescription drugs; over-the-counter pharmaceutical products; health supplements and consumer health products. Geographically activities are functioned through the region of South Korea.
$33
--
$157M
$447M
0.7x
5.0x
South Korea
Hyundai Bioland Co Ltd is engage in provision of raw materials for cosmetic, health food, API, pharmaceuticals, functional foods, and medical devices industry.
$3
--
$92M
$83M
0.9x
6.9x
Median$52-24%$312M$466M1.9x9.4x

Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial